ALUPENT
LOE ApproachingNDAINHALATIONSOLUTION
Approved
Jun 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALUPENT is an inhaled bronchodilator solution approved in 1983 for respiratory indications. The product is a small-molecule sympathomimetic agent delivered via inhalation to manage airway obstruction. It represents a legacy respiratory therapeutic from Boehringer Ingelheim's established portfolio.
LOE Approaching
As LOE approaches, expect workforce restructuring, consolidation of brand teams, and potential transition of personnel to growth-stage products.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ALUPENT offers limited career growth opportunities given its LOE-approaching status and minimal linked job openings. Working on this product is best suited for professionals focused on mature-product optimization, cost management, and wind-down strategies rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on ALUPENT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.